Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications

Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation

(2021) Michelle C. Krutein et al.   Blood Advances

Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignancies

(2020) Elise Fournier et al.   BRITISH JOURNAL OF HAEMATOLOGY

Histone deacetylase 3 preferentially binds and collaborates with transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML

(2020) Chun Guo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The clinical mutatome of core binding factor leukemia

(2020) Sabrina Opatz et al.   LEUKEMIA

A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia.

(2020) Laurène Fenwarth et al.   BLOOD

RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1

(2019) Christopher P Mill et al.   BLOOD

Hematological malignancies and molecular targeting therapy

(2019) Akira Shimada   EUROPEAN JOURNAL OF PHARMACOLOGY

Checkpoint inhibitors in AML: are we there yet?

(2019) Arnab Ghosh et al.   BRITISH JOURNAL OF HAEMATOLOGY

Genomics of Acute Myeloid Leukemia Diagnosis and Pathways

(2017) Lars Bullinger et al.   JOURNAL OF CLINICAL ONCOLOGY

RUNX1 cooperates with FLT3-ITD to induce leukemia

(2017) Kira Behrens et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells

(2017) D T Saenz et al.   LEUKEMIA

A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cells

(2017) Zaw Min Oo et al.   LEUKEMIA & LYMPHOMA

MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia

(2017) K H M Prange et al.   ONCOGENE

ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia

(2017) Jean-Baptiste Micol et al.   Nature Communications

Comprehensive mutational profiling of core binding factor acute myeloid leukemia

(2016) N. Duployez et al.   BLOOD

RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature

(2016) V.-P. Lavallee et al.   BLOOD

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features

(2016) V I Gaidzik et al.   LEUKEMIA

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia

(2016) Lin Fu et al.   Oncotarget

Preclinical study of cinobufagin as a promising anti-colorectal cancer agent

(2016) Xing-sheng Lu et al.   Oncotarget

Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers

(2016) Anuradha Illendula et al.   EBioMedicine

Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells

(2015) Xiongwei Cai et al.   Cell Stem Cell

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial

(2015) C. Willekens et al.   HAEMATOLOGICA

Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice

(2015) R K Hyde et al.   LEUKEMIA

Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia

(2015) I Antony-Debré et al.   LEUKEMIA

Mediator kinase inhibition further activates super-enhancer-associated genes in AML

(2015) Henry E. Pelish et al.   NATURE

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

(2015) Philipp Rathert et al.   NATURE

BET inhibitor resistance emerges from leukaemia stem cells

(2015) Chun Yew Fong et al.   NATURE

A small-molecule inhibitor of the aberrant transcription factor CBF -SMMHC delays leukemia in mice

(2015) A. Illendula et al.   SCIENCE

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial

(2015) C. Willekens et al.   HAEMATOLOGICA

Interplay between Transcription Factors and the Epigenome: Insight from the Role of RUNX1 in Leukemia

(2015) Kate H. Brettingham-Moore et al.   Frontiers in Immunology

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)

(2015) Harald Herrmann et al.   Oncotarget

Downregulation of RUNX1/CBF  by MLL fusion proteins enhances hematopoietic stem cell self-renewal

(2014) X. Zhao et al.   BLOOD

Posttranslational modifications of RUNX1 as potential anticancer targets

(2014) S Goyama et al.   ONCOGENE

Comprehensive mutational profiling in advanced systemic mastocytosis

(2013) J. Schwaab et al.   BLOOD

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

(2013) E. Jourdan et al.   BLOOD

Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells

(2013) Susumu Goyama et al.   JOURNAL OF CLINICAL INVESTIGATION

Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

(2013) Raphaël Itzykson et al.   JOURNAL OF CLINICAL ONCOLOGY

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

(2013) T Haferlach et al.   LEUKEMIA

RUNX1 Is a Key Target in t(4;11) Leukemias that Contributes to Gene Activation through an AF4-MLL Complex Interaction

(2013) Adam C. Wilkinson et al.   Cell Reports

Addiction of t(8;21) and inv(16) Acute Myeloid Leukemia to Native RUNX1

(2013) Oren Ben-Ami et al.   Cell Reports

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes

(2012) P. A. Greif et al.   HAEMATOLOGICA

RUNX family: Regulation and diversification of roles through interacting proteins

(2012) Linda Shyue Huey Chuang et al.   INTERNATIONAL JOURNAL OF CANCER

RUNX1Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

(2012) Jason H. Mendler et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBF  interaction

(2012) L. Cunningham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations

(2011) G. Huang et al.   BLOOD

Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects

(2011) Susumu Goyama et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update

(2011) Ching-Hon Pui et al.   JOURNAL OF CLINICAL ONCOLOGY

RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group

(2011) Verena I. Gaidzik et al.   JOURNAL OF CLINICAL ONCOLOGY

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

(2011) Mark A. Dawson et al.   NATURE

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

(2011) Rafael Bejar et al.   NEW ENGLAND JOURNAL OF MEDICINE

AML1/RUNX1 gene point mutations in childhood myeloid malignancies

(2011) Alexandr Migas et al.   PEDIATRIC BLOOD & CANCER

In vivo toxicological evaluation of Anisomycin

(2011) Zhengle Tang et al.   TOXICOLOGY LETTERS

RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis

(2010) S. Schnittger et al.   BLOOD

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias

(2010) Julien Rocquain et al.   BMC CANCER

RUNX1translocations and fusion genes in malignant hemopathies

(2010) Etienne De Braekeleer et al.   Future Oncology

A Runx1 Intronic Enhancer Marks Hemogenic Endothelial Cells and Hematopoietic Stem Cells

(2010) Cherry Ee Lin Ng et al.   STEM CELLS

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations

(2009) J.-L. Tang et al.   BLOOD

Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells

(2009) F. Lefranc et al.   MOLECULAR CANCER THERAPEUTICS